Astellas Steps Tentatively Into Global Vaccines, Following Path Of Japanese Competitors

Astellas Pharma is making forays into the vaccines segment, with the support of development firm ClearPath Development Company to accelerate the process.

Astellas Pharma Inc. has had minor involvement with vaccines in recent years. But in late 2013, the firm in-licensed worldwide rights for Mymetics Corp.’s preclinical respiratory syncytial virus vaccine. Astellas is developing the vaccine through RSV Corp., a company it formed with support from ClearPath Development Co. in December 2013 [See Deal].

ClearPath is supporting Astellas in identifying and developing vaccine candidates. Each vaccine candidate that goes through the partnership will likely be housed in its own start-up company

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Japan

More from Asia